sonelokimab: Clinical Trials

11 trials of sonelokimab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed, 3 active not recruiting, 2 enrolling by invitation. 7 Phase 3, 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	7	Active not recruiting 3, Completed 2, Enrolling by invitation 2
Phase 2	3	Completed 3
Phase 1	1	Completed 1

Follow sonelokimab: new trials by email Literature Review of sonelokimab trials Research Report on sonelokimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis Sonelokimab - Arthritis, Psoriatic	Phase 3	Enrolling by invitation	MoonLake Immunotherapeutics AG	1560	2025-11-13	2026-09-09
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab - Hidradenitis Suppurativa	Phase 3	Enrolling by invitation	MoonLake Immunotherapeutics AG	835	2025-06-27	2026-06-08
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector Sonelokimab - Relative Bioequivalence	Phase 1	Completed	MoonLake Immunotherapeutics AG	120	2025-06-05	2025-12-09
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) Sonelokimab - Hidradenitis Suppurativa	Phase 3	Active not recruiting	MoonLake Immunotherapeutics AG	35	2024-12-30	2026-05-06
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic	Phase 3	Active not recruiting	MoonLake Immunotherapeutics AG	600	2024-10-15	2026-10-09
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Sonelokimab, Placebo - Arthritis, Psoriatic	Phase 3	Active not recruiting	MoonLake Immunotherapeutics AG	960	2024-10-15	2026-10-09
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab, Placebo - Hidradenitis Suppurativa	Phase 3	Completed	MoonLake Immunotherapeutics AG	422	2024-05-15	2026-08-12
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab, Placebo - Hidradenitis Suppurativa	Phase 3	Completed	MoonLake Immunotherapeutics AG	418	2024-05-14	2026-06-08
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis Sonelokimab, Placebo, Adalimumab - Arthritis, Psoriatic	Phase 2	Completed	MoonLake Immunotherapeutics AG	207	2022-12-13	2026-09-10
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa Sonelokimab (M1095), Adalimumab, Placebo - Hidradenitis Suppurativa	Phase 2	Completed	MoonLake Immunotherapeutics AG	234	2022-04-25	2026-09-09
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis M1095 (Sonelokimab), Placebo, Secukinumab - Psoriasis	Phase 2	Completed	Bond Avillion 2 Development LP	313	2018-07-31	2021-08-03

Conditions studied

Sponsors

Countries

Top investigators

Results publications